The P-III trial evaluating CHIKV VLP (IM) vs PBO in 3254 patients aged 12-64yrs. CHIKV VLP met all the co-primary EPs & was shown to be highly immunogenic in the majority of patients up to 22 days post a single vaccination and demonstrated strong induction of chikungunya neutralizing Abs in 98% of vaccinees in the active group
Induced significant neutralizing Abs in 97% of the patients at 2wks. post vaccination confirming a rapid onset of protective levels of immunity. The vaccine also showed a fast, durable response with high immunity levels at 2wks. and 6mos. post a single vaccination
Additionally, 86% had seroprotective levels of neutralizing Abs at 6mos. post vaccination, was well-tolerated in adolescent and adult population
Ref: Globe Newswire | Image: Bavarian Nordic
Related News:- Bavarian Nordic to Acquire Emergent BioSolutions’ Vivotif, Vaxchora and an Under Developed Chikungunya Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
